Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

BackgroundElexacaftor/Tezacaftor/Ivacaftor (ETI) has demonstrated significant efficacy in enhancing clinical outcomes for patients with cystic fibrosis (CF). Despite this, comprehensive post-marketing assessments of its adverse drug events (ADEs) remain insufficient. This study aims to analyze the A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chengyu Zhu, Zhiwei Cui, Tingting Liu, Siyu Lou, Linmei Zhou, Junyou Chen, Ruizhen Zhao, Li Wang, Yingyong Ou, Fan Zou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Pharmacology
Subjects:	CFTR modulator pharmacovigilance FAERS real world analysis adverse drug events
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1531514/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024
by: Siyu Lou, et al.
Published: (2025-06-01)

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
by: Marta Solís García, et al.
Published: (2025-02-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Elexacaftor/Tezacaftor/Ivacaftor Efficacy in a Cohort of Italian Patients with CFTR Rare Mutations
by: Francesca Lucca, et al.
Published: (2025-03-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Evolution of Lung Disease Studied by Computed Tomography in Adults with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
by: Susana Hernández-Muñiz, et al.
Published: (2025-04-01)

Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study
by: Nicola Perrotta, et al.
Published: (2025-04-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)
by: Tomke Sütering, et al.
Published: (2024-12-01)

Evaluation of Complex Drug Interactions Between Elexacaftor-Tezacaftor-Ivacaftor and Statins Using Physiologically Based Pharmacokinetic Modeling
by: Eunjin Hong, et al.
Published: (2025-03-01)

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01)

Development and Validation of a New LC-MS/MS Method for Simultaneous Quantification of Ivacaftor, Tezacaftor and Elexacaftor Plasma Levels in Pediatric Cystic Fibrosis Patients
by: Alessandro Mancini, et al.
Published: (2025-07-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2025-05-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

A Novel LC-MS/MS Method for the Measurement of Elexacaftor, Tezacaftor and Ivacaftor in Plasma, Dried Plasma Spot (DPS) and Whole Blood in Volumetric Absorptive Microsampling (VAMS) Devices
by: Federica Pigliasco, et al.
Published: (2025-02-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis
by: Michael P. Coughlin, et al.
Published: (2024-10-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis
by: Sofia Campos Silva, et al.
Published: (2025-06-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database
by: Feifei Wang, et al.
Published: (2025-07-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis
by: Carlos Martín de Vicente, et al.
Published: (2024-12-01)

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
by: Hazel Ozuna, et al.
Published: (2025-01-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)